Professor & Mitchell Center Director
The existence of individuals who remain cognitively intact despite the presence of neuropathology normally associated with fully symptomatic Alzheimer’s Disease (AD), also called resilient, suggests that there is an intrinsic way for the human brain to resist (or significantly delay) the events that lead to cognitive impairment in AD. Understanding the involved cellular mechanism(s) would thus reveal a very effective target to develop a novel therapeutic concept centered on inducing cognitive resistance in affected patients. With this ultimate goal in mind, the main research focus of Dr. Taglialatela’s group is to determine the molecular basis of brain/cognitive resilience in the face of AD pathology and to explore approaches to induce such resistance in anyone affected by the disease. Dr. Taglialatela’s group uses autoptic human brains, transgenic animal models and in vitro neuronal systems to interrogate basic molecular mechanisms of synaptic/neuronal resilience and focus on calcineurin inhibitors, neural stem cell derived exosomes (and their miRNA content) and near-infrared light as viable approaches to elicit it.
, Curriculum Vitae , Lab Page